Evidence map›Paper›PMID 37006092›Full record

ArticleLung India : official organ of Indian Chest Society

Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study.

Shambo Samrat Samajdar, Shatavisa Mukherjee, Saibal Moitra, Jyotirmoy Pal, Shashank Joshi, Santanu Kumar Tripathi

Open access · diamondAbstract read
In one paragraph

Article in Lung India : official organ of Indian Chest Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Author's response.Lung India : official organ of Indian Chest Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Shambo Samrat SamajdarConsultant at Diabetes and Allergy-Asthma Specialty Clinic, Kolkata & Clinical Pharmacologist at School of Tropical Medicine, Kolkata, West Bengal, India.
Shatavisa MukherjeeDepartment of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata, West Bengal, India.
Saibal MoitraDepartment of Respiratory Medicine, Division of Allergy and Immunology, Apollo Multispeciality Hospital, Kolkata, West Bengal, India.
Jyotirmoy PalDepartment of Medicine, R G Kar Medical College and Hospital, Kolkata, West Bengal, India.
Shashank JoshiDepartment of Diabetology and Endocrinology, Joshi Clinic, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India.
Santanu Kumar TripathiDepartment of Pharmacology, Netaji Subhas Medical College and Hospital, Patna, Bihar, India.
Lilavati Hospital & Research Centre · INNational Allergy Asthma Bronchitis Institute · INR. G. Kar Medical College and Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cough is a wearisome and exasperating symptom affecting the daily life of the infected patient. Cough due to coronavirus disease 2019 (COVID-19) causes excessive morbidity in human populations globally. Apart from the morbidity associated with cough, it also enhances the transmission of this viral infection through droplets. Therefore, curbing cough is crucial to limit its spread. Patients often administer over-the-counter products and antitussive agents, which have no proven benefit. The present study was undertaken to find out if cough associated with COVID-19 and other indicative clinical outcomes is alleviated with a budesonide/formoterol fixed-dose combination (FDC) metered-dose inhaler (MDI). Materials and Methods: A prospective observational study was conducted in mild COVID-19 patients who presented with a cough score ≥8 at presentation. Patients who were initiated on ICS-LABA MDI were observed as group A and those who were not initiated on MDI were observed as Group B. Cough symptom score (at baseline and on day 3 and day 7), the incidence of hospital admission and/or death, and need for mechanical ventilation were documented. Prescribing patterns of anti-cough medications were also noted and analysed. Results: Compared to group B, a higher mean cough score reduction was noted for group A patients at day 3 and day 7 when compared to the baseline, and this was significant at P < 0.001. A significant negative correlation was also observed between mean latency of MDI initiation from the symptom onset and mean cough score reduction. Analysis of the proportion of patients prescribed medications to treat cough showed that overall, 10.78% did not require these, with a greater proportion in group A compared to group B. Conclusion: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 who were treated with ICS-LABA MDI along with usual care benefitted significantly in terms of symptom reduction compared to usual care.

Indexed as

Budesonide formoterol fixed-dose combination MDIcough symptomsCOVID-19

Identifiers

PMID37006092
PMCPMC10174662
OpenAlexW4322749726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.